Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Cardiometabolic profile moderately unfavourable in middle-aged PCOS patients

24 Jan 2020

Middle-aged women with polycystic ovary syndrome (PCOS) exhibit only a moderately unfavourable cardiometabolic profile despite having an increased body mass index (BMI) and waist circumference, as reported in a study.

The cross-sectional study involved 200 PCOS patients and 200 matched controls, and the average age of the overall population was 51 years. Researchers assessed anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes status. They also calculated 10‐year Framingham risk score, the cardiovascular health score and carotid intima‐media thickness (cIMT).

Compared with controls, PCOS patients were more likely to have increased waist circumference and BMI and were predisposed to hypertension (p<0.001).

There were no significant between-group differences in the prevalence rates of type II diabetes and metabolic syndrome, as well as in lipid levels. However, cIMT was lower in in the PCOS group (p<0.001).

The estimated cardiovascular health and 10‐year cardiovascular disease (CVD) risk were likewise similar in the PCOS and control groups.

Findings of the present study point to a need for long‐term follow‐up of women with PCOS in order to establish the long‐term risk of CVD, the researchers said. “[A]lthough some metabolic disturbances were present in our large cohort of middle‐aged women with PCOS, we found no evidence for premature atherosclerosis or an increased risk for future CVD. Only time will tell whether this will indeed translate into a better cardiovascular health in women with PCOS than was previously anticipated.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.